Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Ratain
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC). If confirmed in a peer-reviewed publication, divarasib will likely become the preferred inhibitor in this disease.
From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping
Obvious chemical substitutions could be used to generate powerful new composition-of-matter patents, highlighting the need for patent and antitrust policy reforms that better separate strategic pursuit of exclusivity from true therapeutic innovation.
Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe
Information & Authors Published In History Published online: January 29, 2026 Permissions Request permissions for this article. Author Contributions Manuscript writing: All authors Final approval of manuscript: All authors Accountable for all aspects of the work: All authors Disclosures Mark J.
Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer
COMMENTS AND CONTROVERSIES Oncology drugs undergo scientific review in the United States by the US Food and Drug Administration (FDA)'s Office of Oncologic Drugs (OOD).
Tag Archive: Patent reform
Post New Patent Office Director Makes Waves with New Rules for Patent Challenges Post Where Does Patent Reform Stand as 2023 Comes to a Close? Post Inside Congress’ Hot Patent Summer Post Where Is Intellectual Property Policy Headed in 2023?
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority
The availability of a drug product without appropriate instructions for use has little utility. Prescription drug labeling is required to provide the essential scientific information needed for safe and effective use and must also be updated when current labeling is inaccurate, false, or misleading. Given the narrow therapeutic index of many drugs, particularly those for serious medical illnesses (e.g., cancer, HIV), information regarding the dosage is of particular importance.
Sotorasib’s Accelerated Approval
Sotorasib’s Accelerated Approval: Wrong Dose and Indication The drug sotorasib, the first inhibitor of non–small cell lung cancer with the KRASG12C mutation, was approved by the US Food and Drug Administration (FDA) under the accelerated approval program in 2021, based on a single-arm trial among patients previously treated with chemotherapy.
Dose optimization of sotorasib: has the burden of proof for the labeled dose been met?
Get full text access Log in, subscribe or purchase for full access. References 1. Skoulidis, F. ∙ Li, B.T. ∙ Dy, G.K. ... Sotorasib for Lung Cancers with KRAS p.G12C Mutation N Engl J Med. 2021; 384:2371-2381 2. de Langen, A.J. ∙ Johnson, M.L. ∙ Mazieres, J. ... Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401:733-746 3. FDA.
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
While therapeutic drug monitoring is a potentially attractive strategy that can be utilized by clinical pharmacologists to optimize drug dosing, the costs and risks must be balanced against the potential benefits. However, there is great uncertainty regarding the optimal population dose for most oncology drugs, given the lack of randomized dose-ranging phase II trials. Therefore, efforts to individualize dosing are for the most part premature for such agents.
Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies
In January 2021, two of us wrote in these pages about our field’s pressing need to pivot away from identifying and deploying the maximum tolerated dose (MTD) when it comes to targeted oncology therapies.1 We argued that, instead, one should be looking for the “optimal dose”—the dose that best balances efficacy and toxicity. We used the newly described KRAS G12C inhibitor sotorasib as a contemporary example of the MTD issue.
Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies
In January 2021, two of us wrote in these pages about our field’s pressing need to pivot away from identifying and deploying the maximum tolerated dose (MTD) when it comes to targeted oncology therapies.1 We argued that, instead, one should be looking for the “optimal dose”—the dose that best balances efficacy and toxicity. We used the newly described KRAS G12C inhibitor sotorasib as a contemporary example of the MTD issue.
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States
Authors: Austin Wesevich, MD, MPH; Monica E. Peek, MD, MPH, MSc; Mark J. Ratain, MD Affiliations: Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois (A.W., M.J.R.) Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois (M.E.P.). Financial Support: By award T32CA009566 from the National Cancer Institute (Dr. Wesevich).
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
The US Food and Drug Administration’s (FDA) Project Optimus, which focuses on new oncology drug dose optimization, was announced in 2021 after approval of sotorasib was conditional on a postmarketing requirement (PMR) to study the efficacy of using 25% of the approved dose.
Oncology Drug Prescribing: The Influences of Greed and Fear
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Both economic and noneconomic decisions are often motivated by greed and fear. Although one would hope that drug prescribing would be evidence-based, greed and fear also factor into such decisions.
Oncology Drug Prescribing: The Influences of Greed and Fear
Enter words / phrases / DOI / ISBN / authors / keywords / etc.
Oncology Drug Prescribing: The Influences of Greed and Fear
Both economic and noneconomic decisions are often motivated by greed and fear. Although one would hope that drug prescribing would be evidence-based, greed and fear also factor into such decisions.
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
Historically, anticancer drugs have been developed and approved for marketing on the basis of the assumption that the optimal dose is the maximum tolerated dose (MTD). That paradigm was well-suited for cytotoxic agents since those drugs typically exhibit a steep dose-response relationship: The more drug administered, the greater the tumor cell kill.
Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical Pharmacologist
Lee et al1 appropriately question the use of historical phase I designs in the context of modern oncology drug development.
The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check
Prostate cancer is the second most common cancer worldwide, estimated to account for more than 1 million cases and more than 350 000 annual deaths.1 Although metastatic prostate cancer remains a lethal malignant neoplasm, the therapeutic landscape has changed drastically during the last decade, most notably with the development of highly potent, orally bioavailable, hormonal therapies targeting the androgen receptor pathway.
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments
The cost of cancer drugs is a challenge to patients and healthcare systems. Here, we propose a new paradigm of near-equivalence, which combines various types of evidence to support acceptability of alternative treatments (ALTs) relative to standard-of-care (SOC).
Empowering the FDA to Require Dose Optimization of All New Oncology Drugs
By Mark J. Ratain, MD, FASCO, and Allen S. Lichter, MD, FASCO January 25, 2021 Advertisement The vast majority of drugs used outside of oncology are evaluated in randomized dose-ranging trials to optimize the therapeutic index prior to the pivotal phase III trial. No one would think of dosing a statin or an antibiotic at the highest dose patients could tolerate, especially if that dose resulted in chronic toxicities.
Empowering the FDA to Require Dose Optimization of All New Oncology Drugs
By Mark J. Ratain, MD, FASCO, and Allen S. Lichter, MD, FASCO Posted: 1/20/2021 2:19:00 PM Last Updated: 1/21/2021 8:39:59 AM Advertisement The vast majority of drugs used outside of oncology are evaluated in randomized dose-ranging trials to optimize the therapeutic index prior to the pivotal phase III trial. No one would think of dosing a statin or an antibiotic at the highest dose patients could tolerate, especially if that dose resulted in chronic toxicities.
Ibrutinib’s Cardiotoxicity-An Opportunity for Postmarketing Regulation
Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) that is indicated for multiple hematological malignancies, including previously untreated chronic lymphocytic leukemia (CLL). This drug is known to have cardiotoxic properties, probably due to off-target inhibition of another kinase. While in randomized trials ibrutinib has been demonstrated to increase survival, some studies have demonstrated fatal toxic effects associated with the drug.
Oncology’s “Hockey Stick” Moment for the Cost of Cancer Drugs
July 2019 was the hottest month in the world’s history. The alarming increase in global temperature was predicted decades ago and made visible by one of the most famous graphs in history: the “hockey stick” graph showing the rise of global temperatures over 1000 years.1 Despite knowing higher temperatures were unavoidable, the world has done little to stem the inexorable rise of carbon emissions and is reaping the consequences.
Applied Clinical Pharmacology in a Crisis - Interleukin‐6 Axis Blockade and COVID‐19
PERSPECTIVE Garth W. Strohbehn Sections of Hematology/Oncology (GWS, MJR) and Rheumatology (PR), Department of Medicine, The University of Chicago Medicine and Biological Sciences, Chicago, IL, USA The Value in Cancer Care Consortium (GWS, MJR), Ann Arbor, MI, USA Search for more papers by this author Pankti D.
Time Is Money: Optimizing the Scheduling of Nivolumab
The checkpoint inhibitors have revolutionized the treatment of many malignant diseases, but there are increasing concerns regarding the cost of prescribing these agents. Although there is no dispute that these drugs are highly effective for some patients, there are opportunities to reduce prescribing costs through a reduction in unit dosage, frequency, or duration of dosing.
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
1. Introduction Brivanib is a small-molecule inhibitor of the vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) family of tyrosine kinase receptors [1x[1]Bhide, R.S., Lombardo, L.J., Hunt, J.T. et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther.
Interventional Pharmacoeconomics
Pharmacoeconomics is an observational science usually focused on the value and affordability of pharmaceutical interventions. We now propose the concept of interventional pharmacoeconomics (IVPE), actively seeking to disruptively decrease prescribing costs through the development of new dosing regimens while maintaining equivalent efficacy. There are at least 4 strategies for IVPE. The first strategy is lower doses.
Precision and Accuracy in the Brave New World of Basket Trials
The Case A 67-year-old man with metastatic cholangiocarcinoma presented to discuss clinical trial options. Somatic genomic testing obtained 1 year earlier demonstrated FGFR2-BEND3 fusion.
The Potential of Value-Based Prescribing in Oncology
By Allen S. Lichter, MD, FASCO, and Mark J. Ratain, MD January 25, 2019 Advertisement Allen S. Lichter, MD, FASCO IT IS TIME for value-based prescribing—the reduction of prescribing costs using basic pharmacologic principles—to be tested and deployed in oncology. The savings are real and there for the taking. If you are concerned about the high costs in cancer care, here is a chance to get maximum value for the dollars spent.
Tumour heterogeneity in the clinic
1.Tran, B. et al. Cancer genomics: technology, discovery, and translation. J. Clin. Oncol. 30, 647–660 (2012).2.Mok, T. S. et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).3.De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508–515 (2008).4.Chapman, P. B. et al.
New Cures Require New Pricing Policies
One critical incentive for ongoing drug discovery and development is the temporary monopoly pricing that manufacturers can command for novel drugs. Yet this incentive, embedded in current patent and regulatory policy, does not guarantee that manufacturers will deliver novel products with clinically meaningful benefits.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack